Failure of second-line therapy to modify survival in relapsed squamous cell carcinoma of the head and neck.
Between August 1979 and August 1984, 47 consecutive patients with recurrent squamous cell carcinoma of the head and neck entered one of three consecutive second-line treatments. Response rates with each treatment were very different (70% vs 5.9% vs 75%), but there was no statistical difference in actuarial survival (survival: 30% vs 29% vs 20%, respectively, at 260 days). In light of this observation, the efficacy of the second-line therapy appears doubtful and the survival of relapsing patients seems unrelated to the response achieved.